ABOS
Acumen Pharmaceuticals, Inc.
Price Chart
Latest Quote
$2.59
Current Price| Previous Close | $2.60 |
| Open | $2.55 |
| Day High | $2.69 |
| Day Low | $2.45 |
| Volume | 441,895 |
Stock Information
| Shares Outstanding | 60.57M |
| Total Debt | $30.84M |
| Cash Equivalents | $126.61M |
| Net Income | $-133.35M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $156.89M |
| EPS (TTM) | $-2.21 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 19/42| Debt to Equity | 0.16 |
| Debt to Earnings | -0.28 |
| Current Ratio | 6.46 |
| Quick Ratio | 6.23 |
| Return on Equity | -56.28% |
| Avg FCF Growth | 94.76% |
| FCF Yield | -54.96% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $2.59 | 442,492 |
| 2026-01-30 | $2.60 | 698,500 |
| 2026-01-29 | $2.79 | 846,600 |
| 2026-01-28 | $2.81 | 2,223,500 |
| 2026-01-27 | $2.72 | 6,491,700 |
| 2026-01-26 | $2.08 | 12,221,700 |
| 2026-01-23 | $1.98 | 141,300 |
| 2026-01-22 | $1.99 | 239,100 |
| 2026-01-21 | $1.81 | 212,400 |
| 2026-01-20 | $1.86 | 73,200 |
| 2026-01-16 | $1.89 | 305,700 |
| 2026-01-15 | $1.86 | 127,500 |
| 2026-01-14 | $1.79 | 221,300 |
| 2026-01-13 | $1.73 | 106,600 |
| 2026-01-12 | $1.72 | 302,200 |
| 2026-01-09 | $1.81 | 284,600 |
| 2026-01-08 | $1.86 | 588,300 |
| 2026-01-07 | $1.99 | 220,200 |
| 2026-01-06 | $1.96 | 166,600 |
| 2026-01-05 | $1.98 | 182,200 |
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
📰 Latest News
Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments
Simply Wall St. • 2026-01-28T02:08:17Z
Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS?
Simply Wall St. • 2026-01-26T10:06:44Z
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks
TipRanks • 2026-01-25T11:05:00Z
January 2026's Rising Stars: Top Penny Stocks To Watch
Simply Wall St. • 2026-01-19T18:05:53Z
Acumen Pharmaceuticals Presents Results on Alzheimer’s Disease at Conference
Exec Edge • 2025-12-02T22:54:43Z
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching
Simply Wall St. • 2025-11-28T18:05:01Z
Acumen Pharmaceuticals Inc (ABOS) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...
GuruFocus.com • 2025-11-12T21:01:41ZUncovering Opportunities: Beauty Health Among 3 Promising Penny Stocks
Simply Wall St. • 2025-10-29T12:05:05Z
Promising Penny Stocks To Watch In September 2025
Simply Wall St. • 2025-09-30T12:05:02Z
Acumen and JCR partner on brain delivery therapy for Alzheimer’s
Pharmaceutical Technology • 2025-07-16T09:04:48Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $4,068,000 | $581,000 | $0 | - |
| Total Expenses | $114,017,000 | $61,138,000 | $45,237,000 | $19,584,000 |
| Other Income Expense | $1,439,000 | $-1,443,000 | $-11,000 | $-81,106,000 |
| Other Non Operating Income Expenses | $-151,000 | $-83,000 | $-11,000 | $51,000 |
| Net Non Operating Interest Income Expense | $10,249,000 | $10,210,000 | $2,392,000 | $84,000 |
| Interest Expense Non Operating | $4,068,000 | $581,000 | $0 | - |
| Operating Expense | $114,017,000 | $61,138,000 | $45,237,000 | $19,584,000 |
| General And Administrative Expense | $20,219,000 | $18,820,000 | $12,876,000 | $7,279,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-102,329,000 | $-52,371,000 | $-42,856,000 | $-100,606,000 |
| Net Interest Income | $10,249,000 | $10,210,000 | $2,392,000 | $84,000 |
| Interest Income | $14,317,000 | $10,791,000 | $2,392,000 | $84,000 |
| Normalized Income | $-103,919,000 | $-51,011,000 | $-42,856,000 | $-19,449,000 |
| Net Income From Continuing And Discontinued Operation | $-102,329,000 | $-52,371,000 | $-42,856,000 | $-100,606,000 |
| Total Operating Income As Reported | $-114,017,000 | $-61,138,000 | $-45,237,000 | $-19,584,000 |
| Net Income Common Stockholders | $-102,329,000 | $-52,371,000 | $-42,856,000 | $-100,606,000 |
| Net Income | $-102,329,000 | $-52,371,000 | $-42,856,000 | $-100,606,000 |
| Net Income Including Noncontrolling Interests | $-102,329,000 | $-52,371,000 | $-42,856,000 | $-100,606,000 |
| Net Income Continuous Operations | $-102,329,000 | $-52,371,000 | $-42,856,000 | $-100,606,000 |
| Pretax Income | $-102,329,000 | $-52,371,000 | $-42,856,000 | $-100,606,000 |
| Interest Income Non Operating | $14,317,000 | $10,791,000 | $2,392,000 | $84,000 |
| Operating Income | $-114,017,000 | $-61,138,000 | $-45,237,000 | $-19,584,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-1.71 | $-1.08 | $-1.06 | $-5.02 |
| Basic EPS | $-1.71 | $-1.08 | $-1.06 | $-5.02 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-99,673,000 | $-50,246,000 | $-42,687,000 | $61,577,000 |
| Total Unusual Items | $1,590,000 | $-1,360,000 | - | $-81,157,000 |
| Total Unusual Items Excluding Goodwill | $1,590,000 | $-1,360,000 | - | $-81,157,000 |
| Reconciled Depreciation | $178,000 | $184,000 | $169,000 | $4,000 |
| EBITDA (Bullshit earnings) | $-98,083,000 | $-51,606,000 | $-42,687,000 | $-19,580,000 |
| EBIT | $-98,261,000 | $-51,790,000 | $-42,856,000 | $-19,584,000 |
| Diluted Average Shares | $60,013,277 | $48,609,383 | $40,601,936 | $20,057,534 |
| Basic Average Shares | $60,013,277 | $48,609,383 | $40,601,936 | $20,057,534 |
| Diluted NI Availto Com Stockholders | $-102,329,000 | $-52,371,000 | $-42,856,000 | $-100,606,000 |
| Gain On Sale Of Security | $1,590,000 | $-1,360,000 | - | $-81,157,000 |
| Research And Development | $93,798,000 | $42,318,000 | $32,361,000 | $12,305,000 |
| Selling General And Administration | $20,219,000 | $18,820,000 | $12,876,000 | $7,279,000 |
| Other Gand A | $20,219,000 | $18,820,000 | $12,876,000 | $7,279,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $181,741,000 | $266,804,000 | $188,775,000 | $225,183,000 |
| Total Assets | $238,992,000 | $310,125,000 | $196,587,000 | $230,330,000 |
| Total Non Current Assets | $60,686,000 | $63,510,000 | $16,258,000 | $31,669,000 |
| Other Non Current Assets | $295,000 | $243,000 | $151,000 | $14,000 |
| Non Current Prepaid Assets | $9,000 | $42,000 | - | - |
| Investmentin Financial Assets | $59,968,000 | $62,553,000 | $15,837,000 | $31,619,000 |
| Goodwill And Other Intangible Assets | $75,000 | $169,000 | - | - |
| Other Intangible Assets | $75,000 | $169,000 | - | - |
| Current Assets | $178,306,000 | $246,615,000 | $180,329,000 | $198,661,000 |
| Other Current Assets | $5,334,000 | $1,963,000 | $1,419,000 | $2,827,000 |
| Prepaid Assets | $1,017,000 | $905,000 | $1,305,000 | $1,597,000 |
| Receivables | $398,000 | $225,000 | $0 | $0 |
| Other Receivables | $345,000 | - | - | - |
| Accrued Interest Receivable | $53,000 | $225,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $171,557,000 | $243,522,000 | $177,605,000 | $194,237,000 |
| Cash And Cash Equivalents | $35,627,000 | $66,886,000 | $130,101,000 | $122,162,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $28,732,000 | $28,487,000 | $105,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $28,599,000 | $27,621,000 | $0 | - |
| Long Term Debt | $28,449,000 | $27,337,000 | - | - |
| Current Debt And Capital Lease Obligation | $133,000 | $866,000 | $105,000 | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $57,176,000 | $43,152,000 | $7,812,000 | $5,147,000 |
| Total Non Current Liabilities Net Minority Interest | $29,569,000 | $30,181,000 | $0 | $0 |
| Derivative Product Liabilities | $970,000 | $2,560,000 | - | - |
| Current Liabilities | $27,607,000 | $12,971,000 | $7,812,000 | $5,147,000 |
| Other Current Liabilities | $230,000 | $212,000 | $131,000 | $204,000 |
| Payables And Accrued Expenses | $23,037,000 | $8,201,000 | $5,568,000 | $3,841,000 |
| Interest Payable | $249,000 | $249,000 | $0 | - |
| Payables | $5,648,000 | $1,379,000 | $1,640,000 | $1,088,000 |
| Accounts Payable | $5,648,000 | $1,379,000 | $1,640,000 | $1,088,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $181,816,000 | $266,973,000 | $188,775,000 | $225,183,000 |
| Total Equity Gross Minority Interest | $181,816,000 | $266,973,000 | $188,775,000 | $225,183,000 |
| Stockholders Equity | $181,816,000 | $266,973,000 | $188,775,000 | $225,183,000 |
| Gains Losses Not Affecting Retained Earnings | $-48,000 | $312,000 | $-751,000 | $-231,000 |
| Other Equity Adjustments | $-48,000 | $312,000 | $-751,000 | $-231,000 |
| Retained Earnings | $-325,127,000 | $-222,798,000 | $-170,427,000 | $-127,571,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $60,094,083 | $57,910,461 | $41,025,062 | $40,473,270 |
| Share Issued | $60,094,083 | $57,910,461 | $41,025,062 | $40,473,270 |
| Tangible Book Value | $181,741,000 | $266,804,000 | $188,775,000 | $225,183,000 |
| Invested Capital | $210,265,000 | $294,310,000 | $188,775,000 | $225,183,000 |
| Working Capital | $150,699,000 | $233,644,000 | $172,517,000 | $193,514,000 |
| Capital Lease Obligations | $283,000 | $1,150,000 | $105,000 | $0 |
| Total Capitalization | $210,265,000 | $294,310,000 | $188,775,000 | $225,183,000 |
| Additional Paid In Capital | $506,985,000 | $489,453,000 | $359,949,000 | $352,981,000 |
| Capital Stock | $6,000 | $6,000 | $4,000 | $4,000 |
| Common Stock | $6,000 | $6,000 | $4,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $0 | $0 | - | - |
| Long Term Capital Lease Obligation | $150,000 | $284,000 | $0 | - |
| Current Capital Lease Obligation | $133,000 | $866,000 | $105,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,207,000 | $3,692,000 | $2,008,000 | $1,102,000 |
| Current Accrued Expenses | $17,389,000 | $6,822,000 | $3,928,000 | $2,753,000 |
| Investments And Advances | $59,968,000 | $62,553,000 | $15,837,000 | $31,619,000 |
| Available For Sale Securities | $59,968,000 | $62,553,000 | $15,837,000 | $31,619,000 |
| Net PPE | $339,000 | $503,000 | $270,000 | $36,000 |
| Gross PPE | $339,000 | $503,000 | $270,000 | $36,000 |
| Other Properties | $339,000 | $503,000 | $270,000 | $36,000 |
| Other Short Term Investments | $135,930,000 | $176,636,000 | $47,504,000 | $72,075,000 |
| Treasury Shares Number | - | $0 | - | - |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-86,231,000 | $-43,085,000 | $-35,314,000 | $-18,001,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-86,215,000 | $-43,064,000 | $-35,153,000 | $-17,961,000 |
| Cash Flow From Continuing Operating Activities | $-86,215,000 | $-43,064,000 | $-35,153,000 | $-17,961,000 |
| Operating Gains Losses | $-1,687,000 | $1,349,000 | - | $81,157,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-16,000 | $-21,000 | $-161,000 | $-40,000 |
| Investing Cash Flow | $48,027,000 | $-171,671,000 | $39,185,000 | $-104,120,000 |
| Cash Flow From Continuing Investing Activities | $48,027,000 | $-171,671,000 | $39,185,000 | $-104,120,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-41,000 | $0 | - | - |
| Issuance Of Capital Stock | $7,938,000 | $121,904,000 | $3,792,000 | $198,587,000 |
| Financing Cash Flow | $6,928,000 | $151,753,000 | $3,907,000 | $200,466,000 |
| Cash Flow From Continuing Financing Activities | $6,928,000 | $151,753,000 | $3,907,000 | $200,466,000 |
| Net Other Financing Charges | $-230,000 | $-476,000 | - | - |
| Cash Dividends Paid | $0 | $0 | - | - |
| Net Common Stock Issuance | $7,897,000 | $121,904,000 | $3,792,000 | $168,556,000 |
| Common Stock Issuance | $7,938,000 | $121,904,000 | $3,792,000 | $168,556,000 |
| Net Preferred Stock Issuance | - | - | $0 | $30,031,000 |
| Preferred Stock Issuance | - | - | $0 | $30,031,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-739,000 | $0 | - | - |
| Issuance Of Debt | $0 | $30,000,000 | $0 | - |
| Interest Paid Supplemental Data | $2,973,000 | $169,000 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $35,859,000 | $67,119,000 | $130,101,000 | $122,162,000 |
| Beginning Cash Position | $67,119,000 | $130,101,000 | $122,162,000 | $43,777,000 |
| Changes In Cash | $-31,260,000 | $-62,982,000 | $7,939,000 | $78,385,000 |
| Interest Paid Cff | $0 | $-476,000 | - | - |
| Proceeds From Stock Option Exercised | $0 | $325,000 | $115,000 | $1,879,000 |
| Common Stock Payments | $-41,000 | $0 | - | - |
| Net Issuance Payments Of Debt | $-739,000 | $30,000,000 | $0 | - |
| Net Long Term Debt Issuance | $-739,000 | $30,000,000 | $0 | - |
| Long Term Debt Payments | $-739,000 | $0 | - | - |
| Long Term Debt Issuance | $0 | $30,000,000 | $0 | - |
| Net Investment Purchase And Sale | $48,043,000 | $-171,653,000 | $39,346,000 | $-104,080,000 |
| Sale Of Investment | $218,774,000 | $78,981,000 | $80,860,000 | $0 |
| Purchase Of Investment | $-170,731,000 | $-250,634,000 | $-41,514,000 | $-104,080,000 |
| Net PPE Purchase And Sale | $-16,000 | $-18,000 | $-161,000 | $-40,000 |
| Sale Of PPE | $0 | $3,000 | $0 | - |
| Purchase Of PPE | $-16,000 | $-21,000 | $-161,000 | $-40,000 |
| Change In Working Capital | $11,653,000 | $3,866,000 | $3,986,000 | $298,000 |
| Change In Other Current Liabilities | $-23,000 | $17,000 | $-137,000 | $0 |
| Change In Other Current Assets | $74,000 | $-70,000 | $-137,000 | $-14,000 |
| Change In Payables And Accrued Expense | $15,258,000 | $4,288,000 | $2,560,000 | $4,193,000 |
| Change In Accrued Expense | $10,989,000 | $4,549,000 | $2,008,000 | $3,636,000 |
| Change In Payable | $4,269,000 | $-261,000 | $552,000 | $557,000 |
| Change In Account Payable | $4,269,000 | $-261,000 | $552,000 | $557,000 |
| Change In Prepaid Assets | $-3,656,000 | $-369,000 | $1,700,000 | $-3,881,000 |
| Other Non Cash Items | $1,350,000 | $884,000 | - | $81,266,000 |
| Stock Based Compensation | $9,635,000 | $6,145,000 | $3,061,000 | $922,000 |
| Amortization Of Securities | $-5,015,000 | $-3,121,000 | $487,000 | $155,000 |
| Depreciation Amortization Depletion | $178,000 | $184,000 | $169,000 | $4,000 |
| Depreciation And Amortization | $178,000 | $184,000 | $169,000 | $4,000 |
| Depreciation | $178,000 | $184,000 | $169,000 | $4,000 |
| Gain Loss On Investment Securities | $-1,687,000 | $1,349,000 | - | $81,157,000 |
| Net Income From Continuing Operations | $-102,329,000 | $-52,371,000 | $-42,856,000 | $-100,606,000 |
| Change In Receivables | - | - | - | $0 |